Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients

Item

http://www.wikidata.org/entity/Q36235176

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Dexamethasone administration d ...... iagnosed glioblastoma patients

@ast

Dexamethasone administration d ...... iagnosed glioblastoma patients

@en

type

Item

label

Dexamethasone administration d ...... iagnosed glioblastoma patients

@ast

Dexamethasone administration d ...... iagnosed glioblastoma patients

@en

prefLabel

Dexamethasone administration d ...... iagnosed glioblastoma patients

@ast

Dexamethasone administration d ...... iagnosed glioblastoma patients

@en

P1476

Dexamethasone administration d ...... iagnosed glioblastoma patients

@en

P2093

Aaron C Spalding

http://www.w3.org/2001/XMLSchema#string

Andrew J Shearer

http://www.w3.org/2001/XMLSchema#string

Brent J Shelton

http://www.w3.org/2001/XMLSchema#string

David A Sun

http://www.w3.org/2001/XMLSchema#string

Li Chen

http://www.w3.org/2001/XMLSchema#string

Lisa B E Shields

http://www.w3.org/2001/XMLSchema#string

Renato LaRocca

http://www.w3.org/2001/XMLSchema#string

Sarah Parsons

http://www.w3.org/2001/XMLSchema#string

T David Bourne

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

P2888

s13014-015-0527-0

P304

222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13014-015-0527-0

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283720329

http://www.w3.org/2001/XMLSchema#string

P6179

1009729804

http://www.w3.org/2001/XMLSchema#string

P698

26520780

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

P932

4628380

http://www.w3.org/2001/XMLSchema#string